98%
921
2 minutes
20
Ovarian cancer, which ranks eighth among global female cancers and fifth in fatality, poses a significant health challenge owing to its asymptomatic early stages. Understanding the pathogenesis requires extensive research. Recent studies have emphasized the role of the gut and cervicovaginal microbiota in ovarian cancer. This review explores the current understanding of the relationship between the microbiome and ovarian cancer, considering the potential of biomarkers in the serum and various tissues. Insights into the influence of the microbiome on treatments, including surgery and chemotherapy, open doors to innovative approaches, such as fecal microbiome transplantation. This synthesis of recent findings provides crucial insights into the intricate interplay between the microbiome and ovarian cancer, thereby shaping diagnostic and treatment strategies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10972291 | PMC |
http://dx.doi.org/10.3390/medicina60030516 | DOI Listing |
Asia Pac J Oncol Nurs
December 2025
Department of Prevention Management, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Objective: To identify and evaluate the methodological quality and psychometric properties of Patient-reported outcome measures (PROMs) for symptom assessment in patients with cancer undergoing immunotherapy.
Methods: A systematic search was performed in PubMed, Scopus, Cochrane Library, Web of Science, Embase, CINAHL, CNKI, WanFang, Vip, and SinoMed from their inception to February 10, 2025. Eligibility criteria required studies to focus on the development or validation of a PROM for symptom assessment in adult patients with cancer undergoing immunotherapy, and to report on at least one psychometric property.
Front Oncol
August 2025
Department of Gynecology, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.
Background: Ovarian cancer (OC) and uterine cancer (UC) are significant public health concerns among women of reproductive age. High body mass index (BMI) contributes to the increasing burden of these cancers globally, but comprehensive epidemiological assessments remain limited.
Methods: Data were obtained from the Global Burden of Disease (GBD) Study 2021 (1990-2021).
Front Oncol
August 2025
Department of Infectious Biology, ICMR-National Institute for Research in Reproductive and Child Health, Mumbai, India.
Introduction: Ovarian cancer has a high mortality rate due to late diagnosis, relapse and chemoresistance. miRNAs play a major role in tumorigenesis as well as chemoresistance. Hence, we undertook a study, to evaluate the differential expression of miRNAs in clinical specimens of ovarian cancer patients that may highlight the effect of chemotherapy and their role in predicting survival outcomes.
View Article and Find Full Text PDFCureus
August 2025
Department of Surgical Oncology, CION Cancer Clinics, Hyderabad, IND.
Extra-ovarian recurrence of mucinous cystadenomas (MCs) is a rare phenomenon. This case report presents the first documented instance of a benign MC recurring within the uterine myometrium of a 48-year-old woman. Two years following an oophorectomy for a large left ovarian MC, the patient presented with lower abdominal pain.
View Article and Find Full Text PDFCureus
August 2025
Department of Nursing Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, JPN.
Objective In 2020, breast cancer was the most commonly diagnosed cancer among women in Japan. Its incidence begins to rise in the late twenties and reaches a first peak in the late forties. Therefore, fostering sustainable preventive health behaviors from a younger age is crucial.
View Article and Find Full Text PDF